8-K: Apyx Medical Reports Q1 2024 Results: Revenue Declines Amidst Economic Headwinds, Reaffirms Full Year Outlook

Apyx Medical reported a 16% year-over-year decrease in total revenue for the first quarter of 2024, while reaffirming its full-year financial guidance.

Summary

• Apyx Medical Corporation announced its financial results for the first quarter of 2024, showing a total revenue of $10.2 million, which is a 16% decrease compared to the same period last year.
• The Advanced Energy segment experienced a 23% year-over-year revenue decrease, totaling $7.5 million, primarily due to lower generator sales.
• OEM revenue increased by 14% year-over-year to $2.8 million, driven by higher sales volume to Symmetry Surgical.
• The company reported a net loss attributable to stockholders of $7.6 million, a significant increase of $4.1 million or 118% compared to the previous year.
• Adjusted EBITDA loss was $5.3 million, which is a $1.3 million or 34% increase year-over-year.
• Gross profit decreased by 21% to $5.9 million, with a gross profit margin of 58.1%, down from 62.4% in the prior year period.
• Operating expenses decreased by 5% to $12.6 million, driven by reductions in selling, general, and administrative expenses, salaries, and professional services.
• The company reaffirmed its full-year 2024 revenue guidance, projecting total revenue between $49.7 million and $52.9 million, which represents a potential decrease of 5% to a growth of 1% year-over-year.
• Advanced Energy revenue for the full year is expected to be between $41.6 million and $44.6 million, while OEM revenue is projected to be between $8.1 million and $8.3 million.
• The net loss attributable to stockholders for the full year is estimated to be between $26.5 million and $24.3 million.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant revenue decline, increased losses, and a challenging market environment. While the company reaffirmed its guidance, the current results are concerning.

Positives

• OEM revenue increased by 14% year-over-year, indicating growth in that segment.
• Operating expenses decreased by 5% year-over-year, showing some cost control.
• The company reaffirmed its full-year 2024 financial guidance, suggesting confidence in future performance.
• The company highlighted the publication of a peer-reviewed article and presentations at industry events, showcasing clinical evidence and market awareness.

Negatives

• Total revenue decreased by 16% year-over-year, indicating a significant decline in sales.
• Advanced Energy revenue decreased by 23% year-over-year, driven by lower generator sales.
• Net loss attributable to stockholders increased by 118% year-over-year, reflecting a substantial deterioration in profitability.
• Adjusted EBITDA loss increased by 34% year-over-year, indicating worsening operational performance.
• Gross profit margin decreased from 62.4% to 58.1%, impacting overall profitability.

Risks

• The company is facing challenges in the cosmetic surgery market due to economic uncertainty and high interest rates, impacting demand for capital equipment.
• Decreased generator sales in the Advanced Energy segment are a significant concern.
• The company's financial performance is sensitive to macroeconomic conditions and consumer spending habits.
• The company's ability to achieve its financial guidance depends on offsetting decreased generator sales with increased handpiece sales.
• The company is subject to regulatory risks, including the need for FDA approvals for its products.

Future Outlook

The company reaffirmed its full-year 2024 financial guidance, projecting total revenue between $49.7 million and $52.9 million, representing a potential decrease of 5% to a growth of 1% year-over-year. They anticipate that decreased generator sales will be offset by increased handpiece sales.

Management Comments

• Our Advanced Energy revenue results in the first quarter were consistent with our previously stated expectations, as sales remained impacted by the challenging environment in the cosmetic surgery market, said Charlie Goodwin, President and Chief Executive Officer.
• As anticipated, Advanced Energy revenue was largely impacted by decreased generators sales, given continued concerns from potential customers about the macroeconomic environment and high interest rates.
• We are reaffirming our 2024 financial guidance today, which continues to assume that Advanced Energy generator demand will remain impacted by consumer reticence to purchase new capital equipment, offset in full, or in part, by growth in handpiece sales.
• We believe our financial resources enable us to pursue our strategic initiatives, and are committed to operating efficiently while positioning Apyx Medical for future growth and value creation when conditions improve.

Industry Context

The results reflect a challenging environment in the cosmetic surgery market, with macroeconomic factors and high interest rates impacting capital equipment purchases. This is consistent with broader trends of economic uncertainty affecting discretionary spending in the medical aesthetics sector. The company's focus on leveraging clinical evidence and new products is a common strategy in this competitive market.

Comparison to Industry Standards

• Apyx Medical's performance is weaker than some of its competitors in the medical device space, particularly those with more diversified product portfolios or less reliance on capital equipment sales.
• Companies like InMode and Cutera, which also operate in the aesthetic device market, have shown more resilience in revenue growth, suggesting Apyx Medical is facing specific challenges.
• The decrease in gross profit margin is concerning, as it indicates pricing pressures or higher costs of goods sold, which is not a positive trend compared to industry benchmarks.
• The significant increase in net loss and adjusted EBITDA loss is also a negative signal, as many medical device companies are focused on improving profitability.

Management Changes

Stakeholder Impact

• Shareholders will be negatively impacted by the decreased revenue, increased losses, and reduced profitability.
• Employees may face uncertainty due to the company's financial challenges.
• Customers may be affected by potential changes in product availability or pricing.
• Suppliers may experience reduced orders due to the company's decreased sales.

Next Steps

• The company will host a conference call on May 9, 2024, to discuss the results and answer questions.
• The company will focus on leveraging its enhanced portfolio of new clinical indications, new products, and clinical evidence to raise market awareness.
• The company will continue to operate efficiently while positioning itself for future growth when market conditions improve.

Key Dates

Keywords

Apyx Medical, Renuvion, Advanced Energy, OEM, Financial Results, EBITDA, Revenue, Net Loss, Medical Devices, Cosmetic Surgery